Deconstructing Psychedelic Therapy in Palliative Care

Palliative care specialists in Australia and Aotearoa New Zealand are increasingly open to psychedelic therapies, signaling a critical shift in how the medical establishment treats existential distress at the end of life. A recent survey of nearly 100 members of the Australian and New Zealand Society of Palliative Medicine reveals cautious optimism for substances like MDMA and psilocybin, challenging the carceral logic of prohibition and offering a potential alternative to both psychiatric medication and medically assisted dying.

Why existential distress is a systemic issue

When we discuss end-of-life care, we are inherently discussing how the medical-industrial complex values certain bodies over others. For disabled, chronically ill, and neurodivergent individuals, the existential distress of approaching death is often compounded by a system that has historically marginalized them. Up to one third of cancer patients report experiencing anxiety and depression. Yet, the default psychiatric response frequently relies on antidepressants, a neoliberal band-aid that prioritizes making marginalized bodies compliant over addressing the structural suffering of existing under late capitalism. The benefits of these pharmaceuticals are often inconsistent and delayed, burdening patients with unwelcome side effects.

It is within this landscape of epistemic injustice that psychedelic therapies emerge as a potentially radical intervention. By combining measured doses with psychological treatment in a controlled setting, substances like MDMA and psilocybin offer a different paradigm. Instead of numbing the psyche, they may help patients deconstruct their fear and find meaning in their final chapters.

What do palliative care doctors think about psychedelics?

To understand how this shift is being received on the ground, researchers surveyed working members of the Australian and New Zealand Society of Palliative Medicine. The findings reflect a profession cautiously engaging with a decolonized approach to healing. Around three quarters of those surveyed disagreed with the notion that psychedelics are inherently unsafe and should not be used clinically. Nearly nine in ten agreed their use warrants further investigation.

Notably, younger doctors and those based in Aotearoa New Zealand were more likely to believe psychedelics could improve patient outcomes, suggesting a generational and perhaps less colonized shift in medical epistemology. Unlike previous studies that highlighted gender divides, this survey found no meaningful difference in attitudes between genders, pointing to a growing intersectional awareness in the field.

Deconstructing the carceral logic of drug prohibition

While the medical optimism is encouraging, the survey also exposed the limits of institutional reform. Half of the doctors agreed psychedelics should remain illegal for recreational purposes, while a slight majority believed they show promise in palliative settings. Two thirds agreed these substances might improve outcomes when combined with psychotherapy.

We must critically examine this distinction between medical and recreational use. The prohibition of psychedelics has always been a tool of racialized state oppression and carceral control, disproportionately weaponized against BIPOC, migrants, and LGBTQIA+ communities. To advocate for medical access while upholding the criminalization of personal exploration reveals a privileged framework. It demands we ask: who gets to access altered states of consciousness, and under whose surveillance?

Psychedelics as an alternative to medically assisted dying

Perhaps the most radical finding is that 84% of doctors were either neutral or agreed that psychedelic therapies could offer an alternative for patients who might otherwise consider medically assisted dying. This reframes the conversation around bodily autonomy and healing justice. In a society that often pushes disabled and chronically ill individuals toward medically assisted dying as a cost-saving measure under extractive capitalism, psychedelics might offer a vital pathway to find peace and agency.

In 12 follow-up interviews, doctors emphasized the importance of safety, patient-centered care, and equity of access. If these treatments are to enter mainstream palliative care, we must ensure they do not become another commodity hoarded by the wealthy. Healing justice demands that marginalized communities have equitable access to these profound tools.

The case for more research and regulatory change

The future of psychedelic therapy in palliative care depends on stronger evidence and regulatory overhaul. Both Australia and Aotearoa New Zealand have recently enacted laws allowing authorised doctors to prescribe psilocybin and MDMA. Clinical trials are already underway, with an ongoing trial of MDMA-assisted therapy in New Zealand showing promising results for cancer patients experiencing existential distress.

Whether these treatments ultimately dismantle the psychiatric-pharmaceutical complex's grip on end-of-life care remains an open question. But we now have a clearer understanding of where clinicians stand, and the door is open to prioritize healing over prohibition.

Can psychedelic therapy replace antidepressants in palliative care?

While current evidence suggests psychedelics may relieve existential distress more effectively than traditional antidepressants for some patients, doctors agree more research is needed to establish their definitive place in clinical practice.

Why are psychedelics currently restricted by the state?

Psychedelics are restricted due to historical carceral policies rooted in the war on drugs, which has functioned primarily as a mechanism of racialized state oppression and social control over marginalized communities.

Do palliative care doctors support psychedelic therapy?

Yes, a recent survey shows nearly nine in ten palliative care specialists in Australia and New Zealand believe psychedelic use warrants further investigation, and three quarters reject the idea that they are inherently unsafe.